日期 影响因子
日期:
2020 年 — 2026 年
2020
2021
2022
2023
2024
2025
2026
影响因子:
–

Effects of lower extremity neuromuscular and mechanical characteristics on running economy and sports performance of long-distance runners under different relative paces

下肢神经肌肉和力学特征对长跑运动员不同相对配速下跑步经济性和运动表现的影响

期刊:Frontiers in Bioengineering and Biotechnology
影响因子:4.8
doi:10.3389/fbioe.2026.1752244
Tan, Zhengze; Li, Zihao; Ding, Yiling; Wang, Dantong; Wang, Yongan
发表日期：2026
文献求助 收藏

Cost-effectiveness of first-line encorafenib plus cetuximab with mFOLFOX6 in BRAF V600E-mutant metastatic colorectal cancer

一线恩考拉非尼联合西妥昔单抗和mFOLFOX6方案治疗BRAF V600E突变转移性结直肠癌的成本效益分析

期刊:iScience
影响因子:4.1
doi:10.1016/j.isci.2026.114977
Shu, Yamin; Shi, Fenghao; Xiong, Jinlin; Zheng, Jienan; Ding, Yiling; Zhang, Wenting; Xu, Pingping; Zhang, Qilin
BRAF
肿瘤
肠癌
肿瘤免疫
发表日期：2026
文献求助 收藏

Cost-effectiveness of sacituzumab tirumotecan versus chemotherapy for patients with metastatic triple-negative breast cancer in China.

在中国，沙妥珠单抗替鲁莫替康与化疗治疗转移性三阴性乳腺癌患者的成本效益分析

期刊:Breast
影响因子:7.9
doi:10.1016/j.breast.2025.104550
Shu Yamin, Tang Ying, Ding Yiling, Xu Pingping, Zhang Qilin
肿瘤
乳腺癌
发表日期：2025
文献求助 收藏

[Retracted] Formyl peptide receptor 2 expression predicts poor prognosis and promotes invasion and metastasis in epithelial ovarian cancer

【已撤稿】甲酰肽受体2表达预示上皮性卵巢癌预后不良，并促进其侵袭和转移

期刊:Oncology Reports
影响因子:3.9
doi:10.3892/or.2025.8922
Xie, Xiaohui; Yang, Mengyuan; Ding, Yiling; Yu, Ling; Chen, Jianlin
信号转导
肿瘤
肿瘤免疫
卵巢癌
发表日期：2025
文献求助 收藏

Myelopreservation effect of trilaciclib in extensive-stage small cell lung cancer (ES-SCLC): a systematic review and meta-analysis with trial sequential analysis of randomized clinical trials

曲拉西利在广泛期小细胞肺癌（ES-SCLC）中的骨髓保护作用：一项系统评价和荟萃分析，以及随机临床试验的序贯分析

期刊:Translational Lung Cancer Research
影响因子:3.5
doi:10.21037/tlcr-2025-67
Ding, Yiling; Deng, Zhijie; Yuan, Xun; Shu, Yamin; Chen, Jing; Cao, Shiyi; Chu, Qian
肺癌
肿瘤
肿瘤免疫
CLC
细胞生物学
发表日期：2025
文献求助 收藏

A kinematic analysis of the hammer throw technique in elite female athletes: a comparative study between Chinese and international competitors

对精英女子运动员链球技术的运动学分析：中国运动员与国际运动员的比较研究

期刊:Frontiers in Physiology
影响因子:3.4
doi:10.3389/fphys.2025.1590350
Liu, Weijie; Ding, Yiling; He, Ruihua; Li, Jianchen
发表日期：2025
文献求助 收藏

Cost-effectiveness analysis of a first-line treatment with cadonilimab plus platinum-based chemotherapy with or without bevacizumab for persistent, recurrent, or metastatic cervical cancer in China: COMPASSION-16 trial

在中国，一项关于卡多尼利单抗联合铂类化疗（加或不加贝伐单抗）一线治疗持续性、复发性或转移性宫颈癌的成本效益分析：COMPASSION-16试验

期刊:Journal of Pharmaceutical Policy and Practice
影响因子:2.5
doi:10.1080/20523211.2025.2464781
Ding, Yiling; Wang, Chunping; Shu, Yamin; Wang, Jinglin; Zhang, Qilin
肿瘤
肿瘤免疫
OMP
宫颈癌
COMP
OMPA
发表日期：2025
文献求助 收藏

Cost-effectiveness of atezolizumab plus bevacizumab versus sorafenib as first-line therapy in unresectable hepatocellular carcinoma in the US and Chinese setting: a modelling comparison study

在美国和中国，阿特珠单抗联合贝伐珠单抗与索拉非尼作为不可切除肝细胞癌一线治疗方案的成本效益分析：一项模型比较研究

期刊:BMJ Open
影响因子:2.3
doi:10.1136/bmjopen-2024-094804
Liu, Lulu; Wang, Lei; Ding, Yiling; Zhang, Qilin; Shu, Yamin
细胞生物学
肿瘤
肿瘤免疫
发表日期：2025
文献求助 收藏

Adverse events with risankizumab in the real world: postmarketing pharmacovigilance assessment of the FDA adverse event reporting system

真实世界中risankizumab的不良事件：FDA不良事件报告系统的上市后药物警戒评估

期刊:Frontiers in Immunology
影响因子:5.9
doi:10.3389/fimmu.2023.1169735
Shu, Yamin; Chen, Jing; Ding, Yiling; Zhang, Qilin
发表日期：2023
文献求助 收藏

Cost-effectiveness of sintilimab plus chemotherapy versus chemotherapy alone as first-line treatment of locally advanced or metastatic oesophageal squamous cell carcinoma

信迪利单抗联合化疗与单纯化疗作为局部晚期或转移性食管鳞状细胞癌一线治疗的成本效益分析

期刊:Frontiers in Immunology
影响因子:5.9
doi:10.3389/fimmu.2023.1092385
Liu, Lulu; Wang, Lei; Chen, Li; Ding, Yiling; Zhang, Qilin; Shu, Yamin
细胞生物学
肿瘤
肿瘤免疫
发表日期：2023
文献求助 收藏